Coultreon Raises $125m To Take Lead SIK3 Inhibitor Into Phase II

Start-Up Focused On Autoimmune, Metabolic Diseases

 
• By Mandy Jackson
  
VC Blocks on Teal Background
Coultreon's series A will fund the company through proof of concept (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Financing

More from Business